( This Biotech Will Get Sickle Cell Approved, Has 18 Drug Approvals, BLUE None. )
See it Market
This Week In IPOs: “Risk-Off”, Boutique Investment Banking And Sickle Cell Disease
August 10, 2015 Investing Research
( GBT )
GBT is developing the initial product candidate, GBT440, as a once-daily, oral prophylactic therapy for sickle cell disease.GBT plans to explore the treatment of more indications, notably hypoxemic pulmonary disorders and hereditary angioedema.
Highlights. Sickle Cell Disease ,Severe disease with major unmet medical need, large marketopportunity. Highly experience team with successful track record in developing and commercializing drugs. Co. has contributed to 18 drug approvals
Baker Bros. Advisors Boosts Stake In Aquinox Pharmaceuticals Inc. (AQXP) to 39.8%
By Gene Guzun in Hedge Funds,NewsPublished: August 11, 2015
will sell in $60's
you sound scared and should be,earnings up 5x's in just a year -incredible growth
This JUNO deal seems to me to be great news for CAR-Ts .It means CELG decided the barriers to entry are high for CAR-Ts.
ill buy then
Fitbit has unbelievable growth and is already profitable, which is a big deal for a newly public company.The valuation is attractive, too. GoPro (GPRO) and Under Armour (UA) both have slower growth rates, yet have higher valuations that Fitbit.
The Fly On The Wall
Breaking News Feed
6/10/2015 Needham & Company LLC Reiterated Rating Positive
Cramer's Mad Dash: FireEye is cheap at this price cybersecurity ...( FEYE )